Document Detail


Treatment of uremic hyperphosphatemia--is there still a need for aluminum salts?
MedLine Citation:
PMID:  3071137     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Aluminum-containing phosphate binders have been widely employed in the past in the management of uremic hyperphosphatemia. However, an increasing number of reports on aluminum toxicity has stimulated efforts to replace this therapy by safer methods. The aim of the present review is to critically evaluate other treatment strategies. It appears that aluminum-containing phosphate binders should no longer be considered the treatment of choice for controlling uremic hyperphosphatemia. Calcium carbonate, calcium citrate, magnesium carbonate and a mixture of ketoanalogues and amino acids present important therapeutical alternatives which could replace aluminum-containing phosphate binders in the majority of patients. However, it is mandatory, as these therapies also carry some risks, that side effects are detected early.
Authors:
K Schaefer; D von Herrath; C M Erley
Related Documents :
938657 - Formation of bile acids in man. metabolism of 7alpha-hydroxy-4-cholesten-3-one in norma...
8325607 - The immunosuppressive effect of ursodeoxycholic acid: a comparative in vitro study on h...
8634807 - The combination of glycolic acid and hydroquinone or kojic acid for the treatment of me...
7461467 - Lack of response to chenodeoxycholic acid in obese and non-obese patients. role of chol...
74937 - Demonstration of mast cell granules by the cetylpyridinium chloride-acid dye (cpc-ad) a...
12013147 - Effect of molecular structures on the solubility enhancement of hydrophobic organic com...
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  American journal of nephrology     Volume:  8     ISSN:  0250-8095     ISO Abbreviation:  Am. J. Nephrol.     Publication Date:  1988  
Date Detail:
Created Date:  1989-05-11     Completed Date:  1989-05-11     Revised Date:  2007-02-14    
Medline Journal Info:
Nlm Unique ID:  8109361     Medline TA:  Am J Nephrol     Country:  SWITZERLAND    
Other Details:
Languages:  eng     Pagination:  173-8     Citation Subset:  IM    
Affiliation:
St. Joseph-Krankenhaus I, Medizinische Abteilung II, Berlin.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Alum Compounds / adverse effects,  therapeutic use*
Aluminum / therapeutic use*
Humans
Phosphates / blood*
Uremia / drug therapy*
Chemical
Reg. No./Substance:
0/Alum Compounds; 0/Phosphates; 7429-90-5/Aluminum

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Significance of cyanide in medicolegal investigations involving fires.
Next Document:  Membranoproliferative glomerulonephritis in a patient with primary Sjögren's syndrome. Report of a ...